ACR exact-submission catalog context
ACR AI Central provides an exact-submission model card for syngo.CT Lung CAD; FDA labeling remains controlling for clinical use, limitations, and performance.
exact submission ยท checked 2026-09-09FDA-cleared profile
syngo.CT Lung CAD
Siemens Medical Solutions, Inc
Authorized purpose: Adjunctive CAD assistance to alert radiologists to potentially overlooked solid pulmonary nodules during chest MDCT review; second-reader use only after the radiologist's initial read.
Evidence status: each field states its source quality, applicability, and review date. Research pending, information not established, and vendor documentation pending remain distinct outcomes.
Product overview
Start with the essentials
Authorized purpose: Adjunctive CAD assistance to alert radiologists to potentially overlooked solid pulmonary nodules during chest MDCT review; second-reader use only after the radiologist's initial read.
Overview status: Source-reviewed overview
- What does this software do? Authorized purpose: Adjunctive CAD assistance to alert radiologists to potentially overlooked solid pulmonary nodules during chest MDCT review; second-reader use only after the radiologist's initial read.
- Which images or clinical context are in scope? Modality: CT/CTA Anatomy or clinical context: Solid pulmonary nodules in the thorax. Input: Thoracic MDCT from Siemens multi-detector CT scanners with four or more detector rows, covering the entire thorax from lung apices to bases; the device is optimized for solid nodules at least 3 mm and less than 20 mm, with cranio-caudal or caudal-cranial scan direction and the table's stated CT input parameters.
- Who uses it? Intended users: Radiologists and trained professionals evaluating the CAD output.
- What does the software produce? Output: A list of nodule candidate locations sent to syngo MM Oncology or another visualization/rendering component, which produces output image series with CAD marks superimposed on the input thoracic CT images.
- What is its most important limitation? Key limitation: The FDA scope is solid pulmonary nodules at least 3 mm and less than 20 mm in diagnostic chest MDCT, with central or peripheral location and round or irregular contour. The device is second-reader only, the output is evaluated by trained professionals, and the original acquired data are not changed.
Clinical takeaway
Clinical role: Adjunctive CAD assistance to alert radiologists to potentially overlooked solid pulmonary nodules during chest MDCT review; second-reader use only after the radiologist's initial read.
Evidence takeaway
Evidence from the reviewed source record: Performance testing found the VC30 standalone sensitivity superior to VC20 and the false-positive rate reduced; true-positive and false-positive marks were reasonably consistent with the predicate in location and extent. The packet states that endpoint definitions and sample size were set in the test protocols but reports no numeric sensitivity, specificity, AUC, PPV, NPV, or reader-delta results.
Clinical details
What this tool is for
Start with the authorized purpose, then verify how it fits your service line and reading workflow.
- Exact purpose
- Adjunctive CAD assistance to alert radiologists to potentially overlooked solid pulmonary nodules during chest MDCT review; second-reader use only after the radiologist's initial read.
- Intended users
- Radiologists and trained professionals evaluating the CAD output.
- Care setting and population
- Diagnostic chest CT reading workflow.
- Workflow role
- Second-reader support after the radiologist completes the initial read, with ROI alerting and full professional review of the case.
- Required input
- Thoracic MDCT from Siemens multi-detector CT scanners with four or more detector rows, covering the entire thorax from lung apices to bases; the device is optimized for solid nodules at least 3 mm and less than 20 mm, with cranio-caudal or caudal-cranial scan direction and the table's stated CT input parameters.
- Output and human action
- A list of nodule candidate locations sent to syngo MM Oncology or another visualization/rendering component, which produces output image series with CAD marks superimposed on the input thoracic CT images.
- Limitations
- The FDA scope is solid pulmonary nodules at least 3 mm and less than 20 mm in diagnostic chest MDCT, with central or peripheral location and round or irregular contour. The device is second-reader only, the output is evaluated by trained professionals, and the original acquired data are not changed.
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
Implementation
Questions for IT, informatics, and operations
Use these fields to structure a vendor demo, security review, and implementation estimate.
- Integration
- The algorithm has no own display UI and sends candidate locations to syngo MM Oncology or a visualization/rendering component; syngo MM Oncology runs on syngo.via for CAD-mark display. Specific local PACS or RIS compatibility is not established.
- Deployment and data flow
- On-premise
Deployment category preserved from the prior exact-submission review; hosting region, data flow, and current commercial configuration still require vendor confirmation.
- Security and privacy
- Vendor documentation pending
Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
- Training and support
- Vendor documentation pending
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
- Monitoring and change control
- Vendor documentation pending
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Evidence
Performance evidence
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
- Evidence summary
- Performance testing found the VC30 standalone sensitivity superior to VC20 and the false-positive rate reduced; true-positive and false-positive marks were reasonably consistent with the predicate in location and extent. The packet states that endpoint definitions and sample size were set in the test protocols but reports no numeric sensitivity, specificity, AUC, PPV, NPV, or reader-delta results.
- Reported sensitivity
- Research pending
This field has not been curated yet.
- Reported specificity
- Research pending
This field has not been curated yet.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
Costs and setup
Budget and ongoing governance
These are common procurement questions; unknown values remain visible until a source supports them.
- Pricing and total cost
- Vendor documentation pending
No public price or quote for the exact K193216 configuration was established in this review.
- Reimbursement and coding
- Not established in reviewed sources
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Safety and lifecycle
Postmarket record
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
- Postmarket safety review
- The exact-identifier FDA recall query returned no native recall record for K193216. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
Buyer worksheet
Open questions to take to the vendor
- Verify security and privacy controls: Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
- Verify training: Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
- Verify pricing and total cost: No public price or quote for the exact K193216 configuration was established in this review.
- Verify reimbursement and coding relevance: No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
- Verify local validation and lifecycle monitoring: Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Research record
What has been checked
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
17Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Sources & history
How this profile was documented
Open the ledger for source dates, scope, and research-record updates.
View source ledger and history
Source ledger
-
FDA K193216: syngo.CT Lung CAD
Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation
-
Artificial Intelligence-Enabled Medical Devices
Scope: regulatoryIdentity, modalityContext
-
syngo.CT Lung CAD model card (K193216)
Scope: anatomy
-
PubMed biomedical literature index
Scope: evidenceDiscovery
-
ClinicalTrials.gov study registry
Scope: evidenceDiscovery, studyStatus
-
openFDA Device Recall API
Scope: recallDiscovery, nativeSubmissionMatching
-
openFDA exact recall query for K193216
Scope: postmarketSafety
Research history
-
K193216 FDA decision
Regulatory record
510(k)
-
Source-review record updated
Research record
fda record reviewed
-
Reader overview source-reviewed
Editorial review
Source-reviewed editorial overlay
Alternatives
Related tools to compare
FDA-cleared K254075
Synapse Lung Nodule AI
Fujifilm Corporation
Concurrent-reader aid for a radiologist detecting pulmonary nodules during review of chest CT examinations in the lung cancer screening population under screening protocols.
- Modality
- CT/CTA
- Anatomy
- Chest/lungs; pulmonary nodules
- Decision
- 2026-05-27
FDA-cleared K251474
Median LCS (internal name) / eyonis LCS (trade name) (1.0)
Median Technologies
eyonis LCS is a concurrent-reading aid for radiologists that detects, localizes, and characterizes 4-30 mm solid and part-solid pulmonary nodules on low-dose chest CT images for...
- Modality
- CT/CTA
- Anatomy
- Chest/Lung
- Decision
- 2026-02-06
FDA-cleared K251769
RevealAI-Lung
Precision Medical Ventures, Inc. Dba Revealdx
Characterization and relative cancer-risk assessment of incidentally detected pulmonary nodules 6-15 mm in adults, with use as one input to follow-up and clinical decision-making...
- Modality
- CT/CTA
- Anatomy
- Pulmonary nodules in the lungs
- Decision
- 2026-01-30
FDA-cleared K240554
InferRead Lung CT.AI
Infervision Medical Technology Co., Ltd.
Adjunctive pulmonary nodule detection and measurement, including temporal comparison, in chest CT screening of asymptomatic adults aged at least 55 years.
- Modality
- CT/CTA
- Anatomy
- Chest/Lung
- Decision
- 2025-05-16